Results 11 to 20 of about 24,552 (280)
Combining BTK inhibitors with BCL2 inhibitors for treating chronic lymphocytic leukemia and mantle cell lymphoma [PDF]
Biomarker Research, 2022 The advent of BTK inhibitors has changed the treatment of patients with chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL). The first-in-class BTK inhibitor ibrutinib has shown remarkable therapeutic effects and manageable toxicities in ...
Jing Zhang +3 more
doaj +2 more sources
Recent Advances in BTK Inhibitors for the Treatment of Inflammatory and Autoimmune Diseases
Molecules, 2021 Bruton’s tyrosine kinase (BTK) plays a crucial role in B-cell receptor and Fc receptor signaling pathways. BTK is also involved in the regulation of Toll-like receptors and chemokine receptors.
Datong Zhang, Fancui Meng
exaly +3 more sources
The Immunomodulatory Functions of BTK Inhibition in the Central Nervous System
Journal of Inflammation Research, 2022 Tingyu Cao,1 Zengguang Wang,2 Xiaodong Zhu1 1Department of Neurology, Tianjin Neurological Institute, Tianjin Medical University General Hospital, Tianjin, People’s Republic of China; 2Department of Neurosurgery, Tianjin Neurological Institute, Tianjin ...
Tingyu Cao +2 more
exaly +2 more sources
Differential impact of BTK active site inhibitors on the conformational state of full-length BTK
eLife, 2020 Bruton’s tyrosine kinase (BTK) is targeted in the treatment of B-cell disorders including leukemias and lymphomas. Currently approved BTK inhibitors, including Ibrutinib, a first-in-class covalent inhibitor of BTK, bind directly to the kinase active site.
Raji E Joseph +5 more
doaj +3 more sources
The race to stymie BTK: zanu zings [PDF]
Blood, 2020 Prashant Kapoor, Steven P. Treon
openalex +3 more sources
Reining in BTK: Interdomain Interactions and Their Importance in the Regulatory Control of BTK [PDF]
Frontiers in Cell and Developmental Biology, 2021 Since Dr. Ogden Bruton’s 1952 paper describing the first human primary immunodeficiency disease, the peripheral membrane binding signaling protein, aptly named Bruton’s tyrosine kinase (BTK), has been the target of intense study. Dr. Bruton’s description of agammaglobulinemia set the stage for ultimately understanding key signaling steps emanating from
Kueffer, Lauren E. +2 more
openaire +3 more sources
Cancer Biology & Medicine, 2022 Objective: B-cell antigen receptor (BCR) signaling is required to maintain the physiological functions of normal B cells and plays an important pathogenic role in B-cell malignancies. Bruton tyrosine kinase (BTK), a critical mediator of BCR signaling, is
Liao Wang +7 more
doaj +1 more source
Megjegyzések a lokális Craig interpolációhoz
Elpis, 2022 Zalán Molnár, Övge Öztürk
doaj +1 more source
Novel antiplatelet strategies targeting GPVI, CLEC-2 and tyrosine kinases
Platelets, 2021 Antiplatelet medications comprise the cornerstone of treatment for diseases that involve arterial thrombosis, including acute coronary syndromes (ACS), stroke and peripheral arterial disease.
Maan H. Harbi +4 more
doaj +1 more source
Structure-based virtual screening and biological evaluation of novel small-molecule BTK inhibitors
Journal of Enzyme Inhibition and Medicinal Chemistry, 2022 Bruton tyrosine kinase (BTK) is linked to multiple signalling pathways that regulate cellular survival, activation, and proliferation. A covalent BTK inhibitor has shown favourable outcomes for treating B cell malignant leukaemia.
Tony Eight Lin +10 more
doaj +1 more source